过去十年来，对于晚期甲状腺癌患者，出现了新的全身治疗选择。然而，对于这些全身治疗在实际使用中的情况知之甚少。本研究利用Optum Clinformatics数据库，对2013年至2021年期间用于晚期甲状腺癌治疗的15种全身治疗方式的使用趋势进行了描述。我们采用Joinpoint回归分析，计算了患者种族/族裔对全身治疗使用的年度百分比变化（APCs）。治疗顺序根据处方索赔的日期确定。2013年至2021年期间，接受全身治疗的晚期甲状腺癌患者人数从2013年的45人增加到2021年的114人（总队列样本数为885人）。大多数患者为女性（54.7％）和非西班牙裔白人（62.1％）。在2013年至2021年期间，接受全身治疗的非西班牙裔白人患者比例显著下降（APC -3.9％，95％ CI -6.0％至-1.8％）。自2015年被FDA批准以来，来那替尼仍然是治疗放射碘难治性甲状腺癌的最常被开处方的一线治疗（2017年至2021年间的患者中占48.8％）。在2017年至2021年期间，大多数患者（79.7％）开始接受十种FDA批准的药物之一，81.7％的患者只接受了一线治疗。2013年至2021年期间，晚期甲状腺癌全身治疗的使用显著增加，这一趋势主要受到2015年FDA批准的来那替尼的开处方推动，非白人患者使用量呈逐渐增加的趋势。版权所有 © 2023. Elsevier Inc. 发表。

In the last decade, new systemic treatment options have been made available for patients with advanced thyroid cancer. However, little is known about the real-world utilization of these systemic therapies.We used the Optum Clinformatics database to characterize trends in the use of 15 systemic therapies that are available for treatment of advanced thyroid cancer between 2013-2021. Joinpoint regression was used to calculate annual percentage changes (APCs) in use of systemic therapy by patients' race/ethnicity. Sequence of therapies were determined by date of prescription claims.Between 2013-2021, the annual number of patients treated for advanced thyroid cancer with systemic therapy increased from 45 patients in 2013 to 114 patients in 2021 (N of total cohort = 885). Most patients were female (54.7%) and non-Hispanic White (62.1%). Between 2013 and 2021, there was a significant decrease in the proportion of non-Hispanic White patients treated for advanced thyroid cancer with systemic therapy (APC -3.9%, 95% CI -6.0% to -1.8%). Since its approval by the FDA in 2015, lenvatinib remains the most frequently prescribed first-line therapy for treatment of radioiodine-refractory thyroid cancer (48.8% of patients between 2017-2021). Between 2017-2021, most patients (79.7%) were initiated on one of the ten FDA-approved agents and 81.7% received only a first-line therapy.Between 2013 and 2021, the use of systemic treatment options for advanced thyroid cancer has increased significantly, largely driven by the prescribing of lenvatinib following its approval by the FDA in 2015, with an increasing trend for use in non-White patients.Copyright © 2023. Published by Elsevier Inc.